Supplementary Table 8 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 93K, Distribution of the PAM50 intrinsic subtypes based on RORP score groups.</p

Supplementary Table 4 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 102K, Clinical-pathological characteristics of the various pathology-defined subtypes.</p

Supplementary Table 7 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 105K, Ability of the high RORP group to predict pCR in 91 patients with clinically HER2-positive disease treated with trastuzumab-based chemotherapy in the ISPY-1, MDACC and XeNA studies.</p

Supplementary Methods, Figure Legends from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 119K</p

Supplementary Table 5 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 104K, Association of the PAM50 Proliferation, RORS and RORP continuous scores with response and event-free survival (EFS).</p

Supplementary Table 2 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 44K, Clinical-pathological comparison of the NOAH and the transNOAH gene expression (GEP) tumor samples.</p

Supplementary Table 6 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 104K, Ability of the HER2-E subtype to predict pCR in 91 patients with clinically HER2-positive disease treated with trastuzumab-based chemotherapy in the ISPY-1, MDACC and XeNA studies.</p

Supplementary Table 3 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 92K, Affymetrix U133A 2.0 probes used for in this study for PAM50 subtyping.</p

Supplementary Table 1 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 77K, CONSORT diagram.</p

Supplementary Figure 1 from Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study

PDF file - 57K, Quality control profiles of the samples.</p